Navigation Links
Gene Therapy Provides Vision to People who Were Nearly Blind
Date:4/27/2008

Results of Clinical Trial Supported by the Foundation Fighting Blindness

are Published in the New England Journal of Medicine

OWINGS MILLS, Md., April 27 /PRNewswire/ -- Scientists employing a gene therapy have provided partial vision to patients who were nearly blind from a condition known as Leber congenital amaurosis (LCA) -- a severe form of retinitis pigmentosa. Initial results from the clinical trial, which was funded in part by the Foundation Fighting Blindness, were published today in the New England Journal of Medicine.

All three patients, who had severely abnormal vision before entering the study, can now read several lines on an eye chart and are able to see better in dimly lit settings. One was also able to navigate better after the injection.

"This breakthrough is the greatest advancement in the 37-year history of the Foundation Fighting Blindness and the entire history of retinal degenerative disease research. We have achieved a critical milestone in curing a form of childhood blindness," says Gordon Gund, Co-Founder and Chairman of the Foundation Fighting Blindness, which is the largest non-governmental source of funding for this research.

"Our clinical trial results represent an important first step in developing therapies and treatments that will reverse blindness in people with a variety of retinal degenerative diseases," says Jean Bennett, M.D., Ph.D., who is the study's lead researcher at The Children's Hospital of Philadelphia.

"The three participants in the Foundation-supported study at The Children's Hospital of Philadelphia are ages 19-26. Though the trial's main goal was to evaluate safety of the treatment, the research team is very excited about the participants' improvements in vision," says Stephen Rose, Ph.D., Chief Research Officer, Foundation Fighting Blindness.

This Phase I study will continue through its planned enrollment of nine individuals between the ages of 8 and 27. T
'/>"/>

SOURCE Foundation Fighting Blindness
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
2. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
3. In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy
4. Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells
5. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
6. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
7. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
8. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
9. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
10. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
11. Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DALLAS , Dec. 23, 2014  Lockton ... operation of Lockton Companies, announced the addition of ... Foerster will join Lockton Dunning,s Pharmacy Consulting team, ... years of relevant industry experience to the position.  ... Managed Market Sales at Diplomat Specialty Pharmacy, where ...
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/24/2014)... and RALEIGH, N.C. , ... of Endo International plc (NASDAQ: ENDP ) ... BDSI ) announced today that they have submitted ... Film to the U.S. Food and Drug Administration (FDA).  ... management of pain severe enough to require daily, around-the-clock, ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... Core Essence Orthopaedics, Inc., a medical device company ... the extremities, has introduced their novel, surgeon-designed PONTiS™ Knotless ... the American Society for Surgery of the Hand (ASSH). ... to the upper and lower extremity markets, Core Essence ...
... 9, 2011 The Board of the European ... it agreed to ratify the proposal of the US Food ... designed with the help of EFCG and US industry representatives, ... Fees Act (GDUFA). GDUFA requires the FDA to ...
Cached Medicine Technology:Core Essence Orthopaedics Unveiled New Flexor Tendon Repair System at ASSH 2011 2European Fine Chemicals Group Ratifies FDA's Proposed Generic Drug User Fees Act (GDUFA) 2
(Date:12/26/2014)... 26, 2014 Cooking and warming ... out of 5. This score reflects slightly positive negotiation ... product specialization, low switching costs and a low level ... the low availability of substitutes for cooking and warming ... steel and aluminum, key inputs in the production process ...
(Date:12/26/2014)... 26, 2014 Plugin and template developers from ... 5 Plugin for Final Cut Pro X. , “TransPack Volume ... tool to pull off an industry professional look” Said Christina ... hands on TransPack Volume 5, a new level of professionalism ... set of over 50 Final Cut Pro X transitions featuring ...
(Date:12/26/2014)... 26, 2014 Pentec Health, Inc. number ... state of Pennsylvania for 2014. The awards program, created ... of its kind in the country. The program is ... Department of Community and Economic Development, the Pennsylvania State ... the Central Penn Business Journal. , Charlie ...
(Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... OAK BROOK, Ill., April 22 The ... of Minnesota have agreed to conditions for ... receive certain services from DeCare Dental following ... certain business functions that DeCare previously performed ...
... patient medical bill clearinghouse is set to help more than 50 ... patient medical debt. IOUSOS™, Powered by GlobeFunder and GlobalTech Collection ... way to deal with aged, unpaid patient bills now totaling an ... ...
... of Driver Technology to Power Artificial Heart Presented at ISHLT ... ... (Vocus) April 22, 2009 -- On April 22-25, SynCardia Systems, ... introduced the new 12-lb Freedom™ discharge driver at the International ...
... Illinois-based leader in physical therapy, fitness, and performance services, recently reached ... Chicago,s Hyde Park neighborhood and 51st center in suburban Naperville. ... ... AthletiCo , an Illinois-based leader in physical therapy, fitness, ...
... clinical supply chain management, announced today that Daniel C. Lubin, a Managing ... www.mhsinc.com , ... Fairfield, Connecticut (PRWEB) April 22, 2009-- ... clinical supply chain management, announced today that Daniel C. Lubin, a Managing ...
... to providing people with skin care information from ... and helpful insights are provided by skin care ... cosmetic dermatology. The content is written by experts ... of practical advice. Key portions of the service ...
Cached Medicine News:Health News:Delta Dental Plans Association and Delta Dental of Minnesota Agree to Conditions Regarding Supplier 2Health News:IOUSOS™ Launches Online Consumer Medical Bill Clearinghouse: New Service Set to Help More than 50 Million Americans and Healthcare Providers 2Health News:IOUSOS™ Launches Online Consumer Medical Bill Clearinghouse: New Service Set to Help More than 50 Million Americans and Healthcare Providers 3Health News:IOUSOS™ Launches Online Consumer Medical Bill Clearinghouse: New Service Set to Help More than 50 Million Americans and Healthcare Providers 4Health News:SynCardia Introduces New 12-lb Freedom Discharge Driver ,Designed to Provide Quality 'Lifestyle' for Total Artificial Heart Patients 2Health News:Illinois-Based AthletiCo Opens Milestone 50th Physical Therapy Center 2Health News:Illinois-Based AthletiCo Opens Milestone 50th Physical Therapy Center 3Health News:Daniel C. Lubin Joins Management Health Solutions, Inc. Board of Directors 2Health News:Beauty-Doctors Website Provides Dermatologist-Authored Skin Care Information from Experts 2
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
Medicine Products: